The phase III Impower150 study randomized patients with chemotherapy-naïve stage IV nonsquamous NSCLC to atezolizumab plus carboplatin/paclitaxel (ACP), bevacizumab (anti-VEGF) plus carboplatin/paclitaxel (BCP), or atezolizumab plus bevacizumab plus carboplatin/paclitaxel (ABCP) [133]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.